Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-03-29
2005-03-29
Wax, Robert A. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S014800, C514S912000, C530S326000, C600S563000
Reexamination Certificate
active
06872705
ABSTRACT:
Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.
REFERENCES:
patent: 4525346 (1985-06-01), Stark
patent: 5171526 (1992-12-01), Wong et al.
patent: 5200453 (1993-04-01), Janssen
patent: 5474979 (1995-12-01), Ding et al.
patent: 5549894 (1996-08-01), Hunt
patent: 5736165 (1998-04-01), Ripley et al.
patent: 5792831 (1998-08-01), Maloy
patent: 5830508 (1998-11-01), MacKeen
patent: 5993864 (1999-11-01), Kross
patent: 6372234 (2002-04-01), Deckers et al.
patent: 6482799 (2002-11-01), Tuse et al.
patent: WO 9625183 (1996-08-01), None
Darveau et al., “Beta-Lactam Antibiotics Potentiate Magainin 2 Antimicrobal Activity In Vitro and In Vivo,” Antimicrobial Agents and Chemotherapy, Jun. 1991, p. 1153-1159.*
Matsuzaki et al., “Mechanism of Synergism between Antimicrobial Peptides Magainin 2 and PGLa,” Biochemistry, 1998, 37, 15144-15153.*
Maria Bishop, “DG Dispatch-ACR: Topical Cyclosporin A Restores Clear Vision to Sjogren's Syndrome Patients”, Doctor's Guide Global Edition, www.pslgroup.com/dg/le96aa.htm, Nov. 3, 2000.
J.H. Lee et al., “High-Level Expression of Antimicrobial Peptide Mediated by a Fusion Partner Reinforcing Formation of Inclusion Bodies”, Biochemical and Biophysical Research Communications 277, 575-580, (2000).
Stevenson, D., MD et al., “Cyclosporin A Ophthalmic Emulsion in the Treatment of Moderate to Severe Dry Eye Disease”, Eye News Late 2000-Richmond Eye Associates from Ophthalmology May 2000; 107:967-974.
Gao J, et al., Abstract of “The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy”, Department of Biological Science, Allergan, Inc. Cornea Nov. 1998; 17(6): 654-63.
Andrew Acheampong et al., “Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs”, Current Eye Research 1999, vol. 18, No. 2, pp. 91-103.
Sall K, et al., Abstract of “Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. ScA Phase 3 Study Group.”, Ophthalmology Apr. 2000;107(4): 631-9.
Stevenson D., Abstract of “Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.”, Ophthalmology May 2000; 107(5):967-74.
Katsumi Matsuzaki, “Why and how are peptide-lipide interactions utilized for self-defence? Magainins and tachyplesins as archetypes”, Biochimica et Biophysica Acta 1462 (1999) 1-10.
David Andreu, “Animal Antimicrobial Peptides: An Overview”, Biopolymers (Peptide Science), vol. 47, 415-433 (1998).
Katsumi Matsuaki, “Magainins as paradign for the mode of action of pore forming polypeptides”, Biochimica et Biophysica Acta 1376 (1998) 391-400.
W. Lee Malloy et al., “Structure-Activity Studies on Magainins and Other Host Defense Peptides”, Biopolymers (Peptide Science), vol. 37, 105-122 (1995).
Michael Zasloff et al., “Antimicrobial activity of synthetic magainin peptides and several analogues”, Proc. Natl. Acad. Sci. USA, vol. 85, pp. 910-913, Feb. 1988, Microbiology.
Allergan Inc.
Hollrigel Greg S.
Stout, Uxa Buyan & Mullins, LLP
Uxa Frank J.
Wax Robert A.
LandOfFree
Use of antimicrobial peptides as preservatives in ophthalmic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of antimicrobial peptides as preservatives in ophthalmic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of antimicrobial peptides as preservatives in ophthalmic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3416642